News

In the laboratory, induced pluripotent stem (iPS) cells can seem like magic: derived from...
Financing will accelerate momentum toward unlocking the linearity between discovery and...
NIH/NIAID SBIR Fast Track grant accelerates the company’s commercial activities towards a non-viral...
The 2021 Cellicon Valley Symposium is presented by Penn’s Abramson Cancer Center and Children’s...
What if a cancer patient could receive life-saving cellular therapy within days of diagnosis rather...
2021 Cell & Gene Meeting on the Med organized by the Alliance for Regenerative Medicine, was held...
Greg Crescenzi Joins Kytopen as Chief Commercial Officer to Drive Discovery, Development and...
BioCentriq™, the New Jersey Innovation Institute’s cell and gene therapy development and...
Kytopen co-founder Professor Cullen Buie studied mechanical engineering, first at Ohio State, then...
MIT spin-out company Kytopen has engaged Cambridge Consultants to co-develop the first Flowfect™...